The purpose of this study is to determine if treatment with pegylated interferon alpha 2b
(peg-IFN-α2b) will reduce the amount of integrated HIV DNA in peripheral blood cells and
tissues of individuals with chronic HIV infection receiving antiretroviral treatment (ART).
A reduction and/or clearance of the latent viral reservoir (i.e.: virus that remains dormant
in HIV-infected subjects receiving suppressive treatment ) is considered essential for HIV
eradication.
By measuring the changes in integrated proviral HIV DNA, which is considered a surrogate
measure of the latent reservoir, the investigators will establish if peg-IFN-α2b treatment
should be considered as a component of future viral eradication strategies.
Phase:
Phase 2
Details
Lead Sponsor:
The Wistar Institute
Collaborators:
Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)